Mastocitosi sistemica indolente: sintomi, diagnosi e nuove terapie

Indolent systemic mastocytosis is a rare, invisible disease that profoundly alters the quality of life of those who suffer from it. In this in-depth analysis by Pianeta Salute TV, discover what this disease really is, why it is diagnosed late, and what new solutions—including podcasts, magazines, and chatbots—are emerging to support patients and doctors. We'll discuss: • What is indolent systemic mastocytosis and what are its real symptoms? • Why mastocytosis is considered a rare, "invisible" disease. • Delayed diagnosis of mastocytosis: why multidisciplinary teams are needed. • How to improve the quality of life of patients with mastocytosis. • New therapies for indolent systemic mastocytosis: where are we now? • What is the MAIA chatbot and how does it help doctors and caregivers? • Sotto la Pelle Podcast: why sharing patients' emotions is crucial. • PRISM Study: how low is the impact on patients' quality of life? Indolent systemic mastocytosis is a rare disease affecting over 6,000 people in Italy, yet it remains poorly understood and often diagnosed years later. Despite its "indolent" name, symptoms can be severe: itching, hives, abdominal pain, chronic fatigue, intestinal problems, and persistent skin blemishes. This condition severely impacts the patient's social, work, and emotional life. From the Milan conference, marking International Mastocytosis Day, three new awareness-raising tools are being released by Blueprint Medicines - A Sanofi Company: 1) "Under the Skin" podcast, dedicated to the emotions of patients and doctors 2) "The Invisible Challenge" magazine, featuring real-life testimonials 3) MAIA chatbot, the first AI assistant in Italy designed to provide reliable scientific information on indolent systemic mastocytosis The Pianeta Salute TV report brings together the voices of specialists, patient associations, and the pharmaceutical industry, highlighting three key themes: ✔ the diagnostic delay ✔ the importance of a multidisciplinary team ✔ the urgent need for targeted therapies and more humane approaches Indolent systemic mastocytosis is not life-threatening, but it profoundly changes life. This is why information, research, and psychological support are an integral part of treatment. If you found this content useful, subscribe to the channel and activate the bell 🔔 to not miss upcoming Pianeta Salute TV reports on rare diseases, prevention, and healthcare innovation. #mastocytosis #disease #qualityoflife #PianetaSaluteTV #healthcare Interviews with: Prof. Massimo Triggiani, hematologist; Patrizia Marcis, president of ASIMAS – Italian Mastocytosis Association; Dr. Marco Frigeni, hematologist, ASST Papa Giovanni XXIII, Bergamo; Dr. Margherita Deiddda, allergist, University Hospital Casula di Monserrato (CA); Stefania Rinaldi, Country Manager Italy Blueprint Medicines - A Sanofi Company. ********************* 🔥 Follow us! WebTV: https://PianetaSalute.TV Magazine: https://www.PianetaSalute.online Instagram:   / pianetasalute2.0   Twitter:   / pianetasalute   Facebook:   / pianetasalute   Linkedin:   / pianeta-salute-tv   WhatsApp: https://whatsapp.com/channel/0029VaDP... Telegram: https://t.me/pianetasalute Digital terrestrial: National Channel 221 Pianeta Salute TV (00:00) - What is indolent systemic mastocytosis? (00:44) - Initiatives to raise awareness and support. (01:36) - Main causes and symptoms. Mastocytosis (3:36) - PRISM Study: Impact on Patients' Quality of Life (5:34) - Daily Difficulties and Delayed Diagnosis (7:25) - Personalized Diagnosis and Treatments (9:00) - Importance of a Multidisciplinary Approach (11:46) - Blueprint Medicines' Commitment and Innovative Tools